125500-84-7

Usage

Uses

Used in Coatings Industry:
ETHYL 2-BUTYRYL-3-ETHOXYACRYLATE is used as a reactive diluent in UV curable coatings, enhancing the curing process and improving the final product's performance characteristics such as adhesion, durability, and resistance to environmental factors.
Used in Adhesives Production:
In the adhesives industry, ETHYL 2-BUTYRYL-3-ETHOXYACRYLATE serves as a monomer, playing a crucial role in the production of adhesives. Its inclusion contributes to the formulation of adhesives with specific properties tailored to various applications, including bonding strength and flexibility.
Used in Specialty Chemicals Synthesis:
ETHYL 2-BUTYRYL-3-ETHOXYACRYLATE is utilized as a building block in the synthesis of specialty chemicals. Its unique chemical structure allows for the creation of novel compounds with specific functionalities, catering to the needs of various industries and applications.
Safety Precautions:
Given its potential hazards, it is imperative to handle ETHYL 2-BUTYRYL-3-ETHOXYACRYLATE with care to avoid ingestion, inhalation, or contact with skin and eyes. Adhering to proper safety measures and precautions during its handling and storage is essential to ensure the well-being of individuals and the integrity of the environment.

InChI:InChI=1/C11H18O4/c1-4-7-10(12)9(8-14-5-2)11(13)15-6-3/h8H,4-7H2,1-3H3/b9-8-

Upstream product

• 3249-68-1 ethyl butyroyl acetate 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 115607-74-4 2-[1-(2-Methoxy-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 126058-91-1 2-[1-(2-Fluoro-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 126059-04-9 ethyl 2-butyryl-3-<(4-hydroxy-2-methoxyphenyl)amino>acrylate 
• 164861-14-7 2-[1-(2-Nitro-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 164861-12-5 2-[1-(2-Hydroxy-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 115607-61-9 3-butyryl-4-(2-methylphenylamino)-8-methoxyquinoline 
• 142782-09-0 1-(8-Methoxy-4-o-tolylamino-quinolin-3-yl)-butan-1-ol 
• 1370287-42-5 ethyl 3-(4-isopropylphenyl)-7-propylpyrazolo[1,5-a]pyrimidine-6-carboxylate 
• 1370287-46-9 3-(4-isopropylphenyl)-7-propylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid 
• 1370287-61-8 3-(4-isopropylphenyl)-N-(2-phenoxyethyl)-7-propylpyrazolo[1,5-a]pyrimidine-6-carboxamide 
• 126058-94-4 2-[1-(2-Acetyl-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 125500-85-8 2-[1-(2-Hydroxymethyl-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 164861-11-4 3-Oxo-2-[1-phenylamino-meth-(Z)-ylidene]-hexanoic acid ethyl ester 
• 1062139-34-7 ethyl (2E)-3-[(4-benzylphenyl)amino]-2-butyrylacrylate 

Relevant academic research and scientific papers

Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A)

A number of pyrazolopyrimidines were synthesized and tested for their positive allosteric modulation of the HCA2 receptor (GPR109A). Compound 24, an efficacious and potent agonist and allosteric enhancer of nicotinic acid's action, was the basis for most other compounds. Interestingly, some of the compounds were found to increase the efficacy of the endogenous ligand 3-hydroxybutyrate and enhance its potency almost 10-fold. This suggests that the pyrazolopyrimidines may have therapeutic value when given alone.

Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABAA receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents (e.g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an α- and a γ-subunit in the GABAA receptor, selected compounds were tested on the α1β2γ2s, α2β2γ2s and α3β2γ2s GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for α1- versus α2- and α3-containing receptors, and high-affinity ligands essentially selective for α1 over α3 were developed.

Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action

3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK and F 96067). In the present study the further structure- activity relatio

Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-Substituted-4- (phenylamino)quinolines

Previously, gastric (H+/K+)-ATPase inhibitors such as 2 have been prepared as analogues of 1a on the presumption that the 3-carbethoxy substituent plays a key role in establishing the orientation of the 4- arylamino group. In this paper we explore further the contribution made to activity by the quinoline 3-substituent. We show that, for compounds bearing such a substituent, only a particular combination of properties provides high activity, both in vitro and as inhibitors of gastric acid secretion in vivo. The ability of the substituent to affect activity by restricting rotation about the C(quin)-N bond through a combination of both a π-electron withdrawal and hydrogen bonding is supported by the current study. However, high activity is only achieved if the effect of this group on the quinoline pK(a) is kept to a minimum. 3-Acyl substituents provide an optimum combination of electronic properties. From this series, compound 17c (SK and F 96067) was shown to be a potent inhibitor of histamine-stimulated gastric acid secretion after oral dosing in the Heidenhain pouch dog and was selected for further development and evaluation in man.